D-galactosamine hepatotoxicity. II. Mechanism of fatty liver production.
D000225:Adenine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D001797:Blood Protein Electrophoresis; D002247:Carbon Isotopes; D005234:Fatty Liver / Q000139:chemically induced*; D005260:Female; D005688:Galactosamine / Q000008:administration & dosage; D005947:Glucose / Q000494:pharmacology; D006595:Hexosamines; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007930:Leucine / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D008099:Liver / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D008862:Microsomes, Liver / Q000032:analysis; D010710:Phosphates / Q000494:pharmacology; D014176:Protein Biosynthesis; D051381:Rats; D011919:Rats, Inbred Strains; D013501:Surface-Active Agents / Q000494:pharmacology; D013997:Time Factors; D014280:Triglycerides / Q000032:analysis / Q000097:blood; D014500:Uracil Nucleotides / Q000494:pharmacology; D014529:Uridine / Q000494:pharmacology
D002247:Carbon Isotopes; D006595:Hexosamines; D008074:Lipoproteins; D010710:Phosphates; D013501:Surface-Active Agents; D014280:Triglycerides; D014500:Uracil Nucleotides; D005688:Galactosamine; D000255:Adenosine Triphosphate; D007930:Leucine; D005947:Glucose; D000225:Adenine; D014529:Uridine